Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immunotherapy combo shows promise for chinese cancer patients

NCT ID NCT03195478

Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 37 Chinese patients with advanced solid tumors that had not responded to prior treatment. The main goals were to check safety and see if the drugs could shrink tumors. The trial is now complete, and results will help determine if this combination is a viable option for this population.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
nivolumab and ipilimumab (immunotherapy drugs)
What this could lead to
If it works, this could offer a new treatment option for Chinese patients with advanced solid tumors that have not responded to other therapies.
What could go wrong
This is an early-phase trial with only 37 participants, so results may not apply to everyone. The combination can cause serious immune-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

37 people

The number who actually took part.

Started

Aug 2017

Finished

Jan 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Mainland Chinese participants with advanced or recurrent solid tumors * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * One prior anti-cancer therapy that did not work or documented refusal to receive chemotherapy or biological therapy Exclusion Criteria: * Cancer that has spread to the brain or central nervous system unless it has been adequately treated . In addition, either no longer receiving corticosteroids, or on a stable or decreasing dose of no more than 10 mg daily prednisone (or equivalent) * Active, known or suspected autoimmune disease or infection * Positive blood screen for chronic infection of hepatitis B or hepatitis C (HCV antibody positive unless HCV RNA is negative) * Prior immuno-oncology therapy Other protocol-defined inclusion/exclusion criteria apply

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Solid tumor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Solid tumor

Contacts and locations

Locations

  • Local Institution

    Guangzhou, Guangdong, 510080, China

  • Local Institution

    Zhengzhou, Henan, 450052, China

  • Local Institution - 0001

    Beijing, Beijing Municipality, 100142, China

  • Local Institution - 0004

    Tianjin, Tianjin Municipality, 300222, China

  • Local Institution - 0011

    Harbin, Heilongjiang, 155040, China

  • Local Institution - 0012

    Guangzhou, Guangdong, 510655, China

  • Local Institution - 0013

    Hangzhou, Zhejiang, 310009, China

  • Local Institution - 0015

    Beijing, Beijing Municipality, 100021, China

  • Local Institution - 0016

    Shanghai, Shanghai Municipality, 200025, China

  • Local Institution - 0018

    Chengdu, Sichuan, 610041, China

  • Local Institution - 0020

    Xi'an, Shan1xi, 710061, China

  • Local Institution - 0021

    Wuhan, Hubei, 430030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.